


PHARMACEUTICAL 2017



Checkpoint Therapeutics Inc. Rank 184 of 313





PHARMACEUTICAL 2017



Checkpoint Therapeutics Inc. Rank 184 of 313

The relative strengths and weaknesses of Checkpoint Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Checkpoint Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 257% points. The greatest weakness of Checkpoint Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 225% points.

The company's Economic Capital Ratio, given in the ranking table, is -281%, being 136% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	35,978
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,673
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-297
Property and Equipment	0
Research and Development	20,267
Revenues	2,570
Selling, General and Administrative Expense	4,467

Output Variable	Value in 1000 USD
Assets	35,978
Liabilities	3,673
Expenses	24,734
Stockholders Equity	32,305
Net Income	-22,461
Comprehensive Net Income	-22,461
Economic Capital Ratio	-281%